title: Recurrent renal salt wasting in a child treated with carboplatin and etoposide.
abstract: BACKGROUND
  Nephrotoxicity of carboplatin is rare, especially in children with normal renal function. A 3-year-old boy had localized esthesioneuroblastoma and received 2 courses of carboplatin (200 mg/m2/day during a 1-hour infusion for 3 consecutive days) associated with etoposide (150 mg/m2/day after carboplatin). Because of a good tumor response, a second course was given 21 days later. Complete surgical excision and local irradiation were performed. However, the tumor recurred a few months later, and the patient subsequently died of the disease.
  
  
  METHODS
  Renal function initially was assessed by standard baseline chemistry and technetium-panetetic acid (Tc-DTPA) clearance. Follow-up included ionic controls and tubular exploration during the episodes of hyponatremia.
  
  
  RESULTS
  Hyponatremia occurred 4 days after completion of the first course and resolved after intravenous supplementation. It recurred 20 days after the second course despite salt and magnesium prehydration and posthydration and resolved 17 days later. No glomerular dysfunction was noticed. The association of urinary bicarbonate loss with elevated N-acetyl-beta-glucosaminidase suggested a proximal tubular damage.
  
  
  CONCLUSIONS
  Standard doses of carboplatin may lead to recurrent renal salt wasting in children with initially normal renal function.
authors.affiliation: Unit of Pediatric Hematology and Oncology, Chu Purpan, Toulouse, France.
authors.forename: C
authors.initials: C
authors.lastname: Tscherning
authors.forename: H
authors.initials: H
authors.lastname: Rubie
authors.forename: A
authors.initials: A
authors.lastname: Chancholle
authors.forename: S
authors.initials: S
authors.lastname: Claeyssens
authors.forename: A
authors.initials: A
authors.lastname: Robert
authors.forename: J
authors.initials: J
authors.lastname: Fabre
authors.forename: F
authors.initials: F
authors.lastname: Bouissou
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D001639:Bicarbonates / Q000097:blood; D001932:Brain Neoplasms / Q000188:drug therapy; D016190:Carboplatin / Q000008:administration & dosage / Q000009:adverse effects*; D002675:Child, Preschool; D018304:Esthesioneuroblastoma, Olfactory / Q000188:drug therapy; D005047:Etoposide / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D007010:Hyponatremia / Q000097:blood / Q000139:chemically induced* / Q000652:urine; D007687:Kidney Tubules, Proximal / Q000187:drug effects; D008297:Male; D012008:Recurrence; D012964:Sodium / Q000097:blood* / Q000652:urine
chemical_list: D001639:Bicarbonates; D005047:Etoposide; D012964:Sodium; D016190:Carboplatin